ALK-TKIs are highly effective in patients with advanced ALK-positive NSCLC, and several ALK-TKIs have been approved for marketing and for first-line treatment of patients with ALK-fusion NSCLC. This evidence concerns the gene ALK and non-small cell lung carcinoma.